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The initial and major emphasis of P-gp research was to explain the occurrence of multidrug resistance in tumors that were initially exposed to a single drug and with time developed resistance to a wide range of other unrelated drugs. Concurrent with the investigation of tumor drug resistance, there have been studies linking this MDR protein with phase I and phase II drug biotransformations, 7 and others have examined the expression and function of P-gp in chloroquineresistant Plasmodium falciparum, the causative organism of malaria. 8 A new focus of interest has been the study of the role of P-gp in transport of many other drugs in addition to cancer chemotherapeutic agents. This transport mechanism may have importance for both drug toxicity and drug-drug interactions. A good example of the latter is the article by Fromm et al 9 in this issue of Circulation. P-gp is a phylogenetically old system that is not restricted to tumor cells but is highly expressed in normal tissues, such as biliary canaliculi, intestinal epithelial cells, proximal tubules of the kidney, adrenal glands, natural killer lymphocytes and capillaries of the central nervous system (CNS), testes, uterus, and skin. 10 Its physiological role is not completely understood, but it could protect against environmental toxins and promote excretion of steroid hormones, drugs, and electrolytes. As shown in the article by Fromm et al, this membrane transporter most likely plays an important part in drug disposition; for example, it has been suggested that normal P-gp function could influence many key steps in drug kinetics, such as reducing gastrointestinal absorption, enhancing bile and urine elimination, and preventing entry of drugs to the CNS. The function of P-gp at the molecular level has been extensively characterized; it is known to be saturable for drugs, as well as osmotically sensitive and ATP dependent.
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P-gp drug substrates represent a wide variety of compounds, most of which are hydrophobic and amphipathic and usually contain electron donor groups arranged in distinct spatial patterns (see Table) . P-gp modulators (also called inhibitors or chemosensitizers) may also be substrates for the transporter; however, this is not a requirement (see Table) . Mechanisms of P-gp modulation include interaction with ligand binding sites on P-gp, inhibition of ATPase, alteration of membrane fluidity, inhibition of protein kinase C (altering the phosphorylation pattern of P-gp), and regulation of MDR gene expression. 4, 11 Past research has focused on decreasing multidrug resistance in oncology to improve the clinical response to chemotherapeutic agents. One attempted strategy has been coadministration of a P-gp substrate and its modulators to enhance exposure to the cytotoxic drug in MDR tumor cells. The understanding that P-gp is expressed in nontumor tissues 10 and that drug distribution is markedly changed in the MDR knockout mouse 12 has led to the hypothesis that modulation of P-gp transport in vivo may lead to reduced drug elimination, increased drug plasma concentration, and increased drug penetrance to tissues such as brain, fetus, and germ cells, with resulting increases in toxicity. The study by Fromm et al 9 tests this hypothesis by examining the clinical interaction between 2 cardiovascular drugs, digoxin and quinidine. The increase in serum digoxin concentrations in patients who receive the combination of digoxin and quinidine has been recognized for 20 years and is the result of a reduction in both the volume of distribution and the clearance of digoxin; however, the exact mechanisms for this response have been poorly understood. 13 Fromm et al report in vitro data from P-gp-expressing cells demonstrating that both drugs are P-gp substrates, and quinidine, at therapeutic concentrations (5 mol/L), inhibits polarized transcellular transport of digoxin. Animal experiments with wild-type and mdr1a knockout mice indicate that quinidine increases the plasma and tissue concentrations of digoxin in P-gp-expressing mice but not in mdr1a Ϫ/Ϫ mice. The present report provides data to support the intriguing speculation that MDR1 expression and/or alteration of its pump function plays a role in other drug-drug interactions and in the access of selected drugs to tissue compartments. For example, MDR1 modulation could change the oral bioavailability, elimination, and CNS penetration of a wide variety of important drugs (see Table) . Among these are commonly prescribed cardiovascular drugs such as calcium channel blockers, quinidine, and amiodarone, whose narrow therapeutic indexes should alert the practicing cardiologist.
Of particular interest to cardiovascular scientists is the fact that P-gp structure and function resemble that of ion channels. It has been hypothesized that P-gp functions as an ion channel, or at least that it regulates ion-transport mechanisms (mainly chloride). 14, 15 It may be relevant that many P-gp modulators are also ion channel blockers (calcium, sodium, and potassium channel blockers; see Table) ; however, the significance of this association is unknown at present. Such an association could be an additional factor contributing to the relevance of some drug interactions to cardiology.
With the current report placed in the context of previous known drug interactions, it is becoming clear that P-gp does indeed have a role in determining drug disposition and drug effects. However, it is still not clear how this influences drug metabolic processes. P-gp may be a component in the defense mechanism against xenobiotics, and drug metabolism is clearly an important step in the detoxification and disposition of xenobiotics. To date, it is known that cytochrome P-450 isoenzymes, particularly 3A (CYP3A), and P-gp share a large number of substrates and modulators and may have complementary roles in drug absorption and disposition 16 ; however, a direct relationship between these 2 processes has yet to be established. For example, drugs that concordantly increase P-gp and CYP3A include rifampicin and phenobarbital. 17, 18 In addition, many drugs have the characteristics of both substrates and inhibitors of P-gp and CYP3A (eg, amiodarone, quinidine, ketoconazole, calcium channel blockers, digoxin, protease inhibitors, cyclosporine, and erythromycin). 19 As understanding of these relationships develops, sources of variability in the first-pass metabolism (gut wall and liver) and pharmacokinetics of drugs may be more completely explained. The interrelationship of the regulatory mechanisms of these 2 systems is an area ripe for further investigation.
Known interactions, such as for quinidine and digoxin, can serve as a model system to better understand the mechanism of this and other frequently occurring drug interactions. As with most aspects of science, a new finding raises more questions than answers; in this particular case, there are still many topics to be clarified, such as the following:
• The functional role of P-gp and related transporters in normal tissues (intestine, liver, kidneys, brain, and heart).
• The precise function of intestinal P-gp as a determinant of drug bioavailability.
• The clinical implications of P-gp modulation. Reserpine *Calcium channel blocker; †potassium channel blocker; ‡sodium channel blocker.
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• The normal variability in expression and function of P-gp (individual differences due to polymorphisms, sex, and/or race).
• The physiological roles of other related transporters, such as the multidrug-associated protein (MRP) and lung resistance protein (LRP). 20 To date, P-gp function and its physiological and clinical roles are still under investigation, but current knowledge suggests that clinicians should be aware of the potential influence of this transport system in drug bioavailability (predominantly oral bioavailability) and drug-drug interactions. Further research will enable us to better evaluate and predict its role in drug disposition, drug-drug interactions, and adverse drug reactions.
